Strategic approaches to antiretroviral treatment. 2003

Diane V Havlir
University of California San Francisco, San Francisco, CA, USA.

A useful clinical framework for decision making in antiretroviral treatment is to consider treatment options and goals at 4 decision points: initial therapy, early treatment failure, late treatment failure with high CD4+ cell count, and late treatment failure with low CD4+ cell count. Basic principles appropriate to these decision points are discussed. For initial treatment, the goal is to suppress viral replication for as long as possible. In early failure, the aim is to achieve resuppression of viral replication. For late treatment failure in patients with high CD4+ cell counts with limited treatment options, a reasonable approach is to be cautious in making treatment changes, since sustained incomplete suppression is not associated with immunologic collapse. In patients with late treatment failure and lower CD4+ cell counts, a reasonable strategy is to maintain some form of antiretroviral therapy until new drug classes become available. These basic approaches are reviewed in this article, with findings reported at the recent 10th Conference on Retroviruses and Opportunistic Infections discussed in light of this strategic framework. This article summarizes a presentation given by Diane V. Havlir, MD, at the March 2003 International AIDS Society-USA course in Los Angeles.

UI MeSH Term Description Entries
D003661 Decision Support Techniques Mathematical or statistical procedures used as aids in making a decision. They are frequently used in medical decision-making. Decision Analysis,Decision Modeling,Models, Decision Support,Analysis, Decision,Decision Aids,Decision Support Technics,Aid, Decision,Aids, Decision,Analyses, Decision,Decision Aid,Decision Analyses,Decision Support Model,Decision Support Models,Decision Support Technic,Decision Support Technique,Model, Decision Support,Modeling, Decision,Technic, Decision Support,Technics, Decision Support,Technique, Decision Support,Techniques, Decision Support
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures
D017410 Practice Guidelines as Topic Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. Clinical Guidelines as Topic,Best Practices,Best Practice

Related Publications

Diane V Havlir
January 2003, AIDS (London, England),
Diane V Havlir
July 2005, Bulletin of the World Health Organization,
Diane V Havlir
June 2004, Pediatric transplantation,
Diane V Havlir
August 1995, Hospital practice (1995),
Diane V Havlir
January 2015, The AAPS journal,
Diane V Havlir
August 1994, Toxicology in vitro : an international journal published in association with BIBRA,
Diane V Havlir
November 2012, Advances in nutrition (Bethesda, Md.),
Diane V Havlir
September 1979, Family process,
Diane V Havlir
January 2005, Cell research,
Diane V Havlir
January 2008, Drug discovery today,
Copied contents to your clipboard!